TXG Company Profile and Key Details

Q: Who are the executives of TXG?

Mr. James BryantDirector of LegalMr. Nikhil RaoDirector of Product ManagementMr. Jonathan SchimmelVice President of Global Support & Sales OperationsMr. Eric S. Whitaker Esq.Chief Legal OfficerMs. Rebecca PortChief People OfficerMr. Justin J. McAnearChief Financial OfficerDr. Benjamin J. Hindson Ph.D.Co-Founder, Pres, Chief Scientific Officer & DirectorMr. Michael Schnall-LevinFounding Scientist & Chief Technology OfficerMs. Ruth De BackerChief Bus. OfficerMs. Cassie CorneauMang. of Investor Relations and Strategic Fin.Mr. Jim Wilbur Ph.D.Chief Commercial OfficerMr. James L. Wilbur Ph.D.Chief Commercial OfficerDr. Serge Saxonov Ph.D.Co-Founder, Chief Executive Officer & Director

NASDAQ : TXG

10x Genomics

$24.52

-0.8287-3.27%

Open: 10:33 AM

63.61

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

10x Genomics, Inc. (TXG) stock declined over -3.27%, trading at $24.52 on NASDAQ, down from the previous close of $25.35. The stock opened at $25.36, fluctuating between $24.29 and $25.57 in the recent session.

Stock Snapshot

25.35

Prev. Close

3.13B

Market Cap

24.29

Day Low

-70.06

P/E Ratio

-0.35

EPS (TTM)

-0.55

Cash Flow per Share

25.36

Open

127.75M

Number of Shares

25.57

Day High

87.83%

Free Float in %

6.25

Book Value

373.97K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	24.19	25.29	23.95	24.80	2.84M
Apr 13, 2026	23.25	24.30	22.91	23.58	2.41M
Apr 10, 2026	23.25	23.63	22.56	23.27	1.74M
Apr 09, 2026	22.88	23.30	22.21	23.00	2.12M
Apr 08, 2026	23.10	23.65	22.42	23.02	2.64M
Apr 07, 2026	21.77	22.15	21.36	21.82	1.98M
Apr 06, 2026	22.35	22.74	21.79	21.89	3.19M
Apr 02, 2026	21.40	22.91	21.11	22.33	1.28M
Apr 01, 2026	21.62	23.06	21.62	22.05	2.43M
Mar 31, 2026	21.00	21.37	20.28	21.23	2.57M
Mar 30, 2026	19.65	19.89	19.22	19.81	1.51M
Mar 27, 2026	20.07	20.14	19.15	19.48	2.05M
Mar 25, 2026	20.20	21.12	19.82	20.91	2.73M
Mar 24, 2026	18.78	19.90	18.77	19.81	1.6M
Mar 23, 2026	18.54	19.48	18.30	19.14	2.99M
Mar 20, 2026	18.42	18.65	18.09	18.39	2.33M
Mar 19, 2026	16.99	18.44	16.85	18.38	1.74M
Mar 18, 2026	17.92	18.04	17.24	17.35	2.35M
Mar 17, 2026	16.79	18.15	16.69	18.09	2.6M
Mar 16, 2026	19.12	19.27	15.90	16.69	5.6M

Contact Details

Pleasanton, CA 94588-3260

United States

https://www.10xgenomics.com 925 401 7300

About Company

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Stock Peers

BTSGU

-0.13-0.08%

BrightSpring Health Services, Inc. Tangible Equity Unit$153.75 NUTX

1.57+1.48%

Nutex Health, Inc.$107.84 HQY

1.45+1.81%

HealthEquity, Inc.$81.36 GEHC

0.84+1.14%

GE HealthCare Technologies Inc.$74.67 WGS

5.88+9.64%

GeneDx Holdings Corp.$66.86 TEM

3.55+7.72%

Tempus AI, Inc.$49.53 BTSG

0.01+0.02%

BrightSpring Health Services, Inc. Common Stock$46.04 OMCL

1.32+3.77%

Omnicell, Inc.$36.33 HTFL

1.62+5.91%

Heartflow, Inc. Common Stock$29.05 PINC

0.09+0.32%

Premier, Inc.$28.26

Company Overview

10x Genomics, Inc. (NASDAQ:TXG) closed at $24.52 USD, losing -$0.83 (-3.27%) from the previous close of $25.35. The stock is currently within 5% of its 52-week high $7.25 and $25.69. With a market capitalization of about $3.13 billion, 10x Genomics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.17). Key stats such as the average daily volume over the past year has been around 2.53 million shares, volume is running light vs its 52-week average. Headquartered in Pleasanton, CA, 10x Genomics, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Serge Saxonov, the company employs approximately 1,306 people and listed since September 12, 2019. 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.

Technical Performance

TXG has shown sold momentum, gaining 11.36% over the past week and 86.39% over the past quarter, though year-to-date performance is up 35.19%. Short-term trend indicators are bearishly aligned (SMA20 15.23%, SMA50 16.33%, SMA200 52.91%). The stock’s 14-day RSI is 65.42 (firm momentum), while the ATR of 1.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.07% below its high and over 226.4% above its low. Average 10-day trading volume of 2.42 million shares is in line with the 3-month average of 2.51 million, indicating normal recent market interest.

Valuation Metrics

10x Genomics, Inc. trades at a P/E ratio of -72.48, slightly below the S&P 500 average, with a price-to-sales ratio of 4.94 and a price-to-book ratio of 3.96 trading at moderately above to book value. The P/FCF stands at 24.38, also below market averages.

Dividend & Fair Value

10x Genomics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $15.21. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

10x Genomics, Inc. generated EPS of -$0.35 over the past year. Five-year average earnings growth is 42.1%. Wall Street analysts project EPS growth of -14.57% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.27. Next year's EPS is expected at $32.77. Analyst sentiment is neutral. Analyst rating data shows there are 7 Strong Buy ratings, 4 Buy ratings, 13 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $13.00. The high target offers 162.1% upside. The low target suggests -47.58% downside. The mean target is $20.46. This offers -17.5% upside. 10x Genomics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 214.29%. The prior quarter beat by -180.0%. Over the last six quarters, Apple has recorded several small beats. These include -32.84% in August 08, 2024.

Shareholding & Insider Activity

10x Genomics, Inc. has 114.41 million shares outstanding. The public float is 112.35 million shares, elevated short interest at 17.71% of float. This equals 13.74 million shares. The short ratio is 4.51 days. Institutional investors hold 111.11% of the float. Insiders own 1.82%. Saxonov Serge holds 1.17 million shares, Hindson Benjamin J. has 424.78 thousand shares and STUELPNAGEL JOHN R has 333.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 84.30 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, 10x Genomics generated $618.73M in revenue, or $5.28 per share. Gross margin was 66.15%, operating margin -32.63%, and net profit margin -41.23%. Returns are negative, with ROA at -26.43% and ROE at -34.42%.
On valuation metrics, 10x Genomics trades at a P/E of -72.48, P/S of 4.94 and P/B of 3.96. The current ratio is 4.46 and quick ratio is 4.09. Operationally, the company’s inventory turnover is 3.53 and cash conversion cycle is 126.85 days. Debt-to-equity is 0.20, supported by a cash flow-to-debt ratio of 0.86.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, 10x Genomics posted revenue of $618.73M, down slightly from $516.41M in the prior quarter. Gross profit was $409.31M (margin 66.15%). Operating income was - $201.87M (margin -32.6%). Net income was- $255.10M (EPS - $2.18).
The company ended the quarter with $388.70M in cash and short-term investments, a total debt of $95.37M, and net debt of - $263.91M. Total assets were $965.14M, with equity of $741.04M. Financials further reflected weakness, with operating cash flow of - $15.20M, free cash flow of - $64.72M, and capital expenditures of - $49.52M.

Price Forecast & Outlook

Our AI price prediction model suggests that 10x Genomics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.43%, with price expected at $25.65 by April 28, 2026, within a range of $23.79 to $27.54 3-Month Outlook: Projected rise of 71.73%, reaching $42.59 by July 13, 2026, with a range of $41.30 to $44.38. 1-Year Outlook: Projected loss of -57.7%, with price at $10.49 by April 14, 2027, within a range of $7.52 to $14.23.

Key Takeaways

10x Genomics, Inc. (NASDAQ:TXG) shares are up 35.19% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows 10x Genomics, Inc. trading at a premium to the broader market with a P/E of -72.48. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $40.06, suggesting 61.53% upside. Our AI forecast model points to short-term strength (3.43% over two weeks), a medium-term rise (71.73% over three months), and a longer-term loss (-57.7% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current 10x Genomics, Inc. (TXG) stock price?

10x Genomics, Inc. (NASDAQ: TXG) stock price is $24.52 in the last trading session. During the trading session, TXG stock reached the peak price of $25.57 while $24.29 was the lowest point it dropped to. The percentage change in TXG stock occurred in the recent session was -3.27% while the dollar amount for the price change in TXG stock was - $0.83.

TXG's industry and sector of operation?

The NASDAQ listed TXG is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector. 10x Genomics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TXG?

Mr. James Bryant
Director of Legal
Mr. Nikhil Rao
Director of Product Management
Mr. Jonathan Schimmel
Vice President of Global Support & Sales Operations
Mr. Eric S. Whitaker Esq.
Chief Legal Officer
Ms. Rebecca Port
Chief People Officer
Mr. Justin J. McAnear
Chief Financial Officer
Dr. Benjamin J. Hindson Ph.D.
Co-Founder, Pres, Chief Scientific Officer & Director
Mr. Michael Schnall-Levin
Founding Scientist & Chief Technology Officer
Ms. Ruth De Backer
Chief Bus. Officer
Ms. Cassie Corneau
Mang. of Investor Relations and Strategic Fin.
Mr. Jim Wilbur Ph.D.
Chief Commercial Officer
Mr. James L. Wilbur Ph.D.
Chief Commercial Officer
Dr. Serge Saxonov Ph.D.
Co-Founder, Chief Executive Officer & Director

How TXG did perform over past 52-week?

TXG's closing price is 242.07% higher than its 52-week low of $7.25 where as its distance from 52-week high of $25.69 is -1.94%.

How many employees does TXG have?

Number of TXG employees currently stands at 1,306.

Link for TXG official website?

Official Website of TXG is: https://www.10xgenomics.com

How do I contact TXG?

TXG could be contacted at phone 925 401 7300 and can also be accessed through its website. TXG operates from 6230 Stoneridge Mall Road, Pleasanton, CA 94588-3260, United States.

How many shares of TXG are traded daily?

TXG stock volume for the day was 373.97K shares. The average number of TXG shares traded daily for last 3 months was 2.53M.

What is the market cap of TXG currently?

The market value of TXG currently stands at $3.13B with its latest stock price at $24.52 and 127.75M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1306
Beta	2.17
Sales or Revenue	$618.73M
5Y Sales Change%	-0.517%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Healthcare Information Services

TXG Company Profile and Key Details

10x Genomics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook